News

The acquisition is a significant step in AstraZeneca’s strategy to transform cancer treatment by offering more targeted therapies as alternatives to traditional treatments like chemotherapy and radiotherapy. RCs,

Abecma is a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell immunotherapy. The ODAC validated the favourable benefit/risk profile of the therapy based on findings from the Phase

EQT Life Sciences and Nextech Invest jointly led the financing round with contributions from new US-based investors, Frazier Life Sciences and Deep Track Capital. Existing investors including Andera

The allogeneic CAR-T product candidate is being developed in partnership with Roche for relapsed/refractory multiple myeloma (RRMM). P-BCMA-ALLO1 targets the B-cell maturation antigen (BCMA) and is enriched with

The submission is scheduled for mid-2024, following constructive pre-submission meetings with EU regulatory authorities. The company also plans to engage with the US Food and Drug Administration (FDA)

A dual-acting IL-23 inhibitor, TREMFYA acts on both IL-23 and CD64 to potentially provide relief for patients. The sBLA is based on the data from the Phase III

This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company. As per the latest approval, the treatment is indicated for reducing risks of major

Following the analysis of cambritaxestat’s chemical and biological properties, including a promising non-clinical safety and efficacy profile, the US regulator granted the ODD status. This designation provides benefits

The fundraising was spearheaded by Enavate Sciences, with Viking Global Investors and Perceptive Advisors joining as new investors. The financing round also saw contributions from all current stakeholders,